분자영상 및 방사화학

본문글자크기
  • [Cancer Biother Radiopharm.] Imaging of Integrin αvβ3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99mTc-IDA-D-[c(RGDfK)]2.

    2017년 11월호
    [Cancer Biother Radiopharm.] Imaging of Integrin αvβ3 Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer 99mTc-IDA-D-[c(RGDfK)]2.

    서울의대/ 송요성, 박현수,김상은*

  • 출처
    Cancer Biother Radiopharm.
  • 등재일
    2017 Oct
  • 저널이슈번호
    32(8):288-296. doi: 10.1089/cbr.2017.2233.
  • 내용

    바로가기  >




    Abstract

    Integrin αvβ3 is a molecular marker for the estimation of tumor angiogenesis and is an imaging target for radiolabeled Arg-Gly-Asp (RGD) peptides. In this study, the authors investigated the clinical efficacy and safety of a novel radiolabeled RGD peptide, 99mTc-IDA-D-[c(RGDfK)]2, for the imaging of integrin αvβ3 expression, as a measure of tumor angiogenesis in lung cancers and brain tumors. Five patients with lung cancers and seven with brain tumors underwent 99mTc-IDA-D-[c(RGDfK)]2 single-photon emission computed tomography (SPECT) imaging. Tumors were also assessed using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Uptake of the radiotracer was expressed as the tumor-to-normal uptake ratio (TNR). All the lung cancers and brain tumors were well visualized on 99mTc-IDA-D-[c(RGDfK)]2 SPECT. TNR for 99mTc-IDA-D-[c(RGDfK)]2 was significantly higher than that for 18F-FDG in brain tumors (6.4 ± 4.1 vs. 0.9 ± 0.4). Proliferation index of brain tumors showed a significant positive correlation with TNR for 99mTc-IDA-D-[c(RGDfK)]2 and 18F-FDG. No laboratory and clinical adverse events were reported after 99mTc-IDA-D-[c(RGDfK)]2 injection. Their results suggest that 99mTc-IDA-D-[c(RGDfK)]2 is an efficacious and safe radiotracer for imaging integrin αvβ3 expression with potential application to monitoring the clinical efficacy of antiangiogenic agents in malignant tumors. In addition, this is the first clinical application of radiolabeled RGD peptides for SPECT imaging of brain tumors. 

     

    Author information

    Song YS1, Park HS1,2, Lee BC1,3, Jung JH1, Lee HY1, Kim SE1,2,3.

    11 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine , Seoul, Republic of Korea.22 Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University , Seoul, Republic of Korea.33 Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence Technology , Suwon, Republic of Korea. 

  • 키워드
    99mTc-IDA-D-[c(RGDfK)]2; brain tumor; integrin αvβ3 expression; lung cancer; single-photon emission computed tomography
  • 연구소개
    본 연구에서는, 종양에서 혈관신생을 반영하는 integrin αvβ3에 대한 신규 바이오마커 99mTc-IDA-D-[c(RGDfK)]2의 영상 소견 및 임상 적용에 대하여 소개함. 단일광자단층촬영 (single photon emission computed tomography, SPECT)을 이용하여 본 뇌종양과 폐암 환자의 영상에서 99mTc-IDA-D-[c(RGDfK)]2의 섭취가 유의한 정도로 증가하였으며, 환자에 대한 임상적용 과정에서도 부작용 없이 그 안전성이 규명되었음.
  • 덧글달기
    덧글달기
       IP : 3.17.23.130

    등록